相关实验视频
Updated: Jun 17, 2025
10:42
A Free-breathing fMRI Method to Study Human Olfactory Function
Published on: July 30, 2017
9.6K
在阿尔茨海默病的嗅觉功能障碍研究的当前状态和挑战
Wanchen Liao1, Yulin Wang1, Lei Wang1
1Department of Alzheimer's Disease Clinical Research Center, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.
Ageing research reviews
|August 10, 2024
概括
嗅觉功能障碍,阿尔茨海默氏症 (AD) 的症状,可以使用嗅觉测试早期检测. 这些测试与其他生物标志物相结合,显示出在轻度认知障碍 (MCI) 之前诊断AD的前景.
科学领域:
- 神经科学是一个神经科学.
- 医学诊断 医学诊断 医学诊断
- 认知科学 认知科学
背景情况:
- 嗅觉功能整合了复杂的认知过程和神经系统.
- 嗅觉中断导致嗅觉功能障碍,这是阿尔茨海默氏症 (AD) 等疾病的潜在早期指标.
- 大脑成像和脑电图 (EEG) 显示了阿兹海默症患者的嗅觉区域的变化.
研究的目的:
- 探索嗅觉功能障碍在阿尔茨海默氏病 (AD) 临床前检测中的潜力.
- 评估嗅觉测试对早期阿尔茨海默病诊断的有用性,在轻度认知障碍 (MCI) 之前.
主要方法:
- 使用医学成像和脑电图 (EEG) 来观察大脑嗅觉区域的变化.
- 由于其高特异性,在社区群体中进行选时应用嗅觉测试.
- 研究嗅觉测试与其他生物标志物的组合,以提高AD预测.
主要成果:
- 嗅觉功能障碍是检测AD在临床前阶段的重要指标.
- 嗅觉测试显示,在一般人群中查AD的特异性很高.
- 将嗅觉测试与其他生物标志物的结合可以提高早期AD诊断的准确性.
结论:
- 嗅觉功能障碍是早期发现阿尔茨海默病 (AD) 的有希望的生物标志物.
- 特定的嗅觉测试是临床前AD查的宝贵工具.
- 结合嗅觉评估和其他生物标志物的综合诊断模型可以提高早期AD诊断的敏感性和特异性.
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171